44 minutes ago
Qazi discusses tofacitinib’s role in acute severe ulcerative colitis management as a potential first-line therapy to increase treatment responsiveness.
56 minutes ago
Dermatology experts highlight VISIBLE trial results when using guselkumab in patients with skin of color.
1 hour ago
Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai discuss VISIBLE trial, a randomized clinical trial specifically designed to examine treatment outcomes with guselkumab in patients with skin of color.
1 hour ago
Findings from a novel study supports the JAK inhibitor tofacitinib as a potential first-line therapy for ASUC.
2 hours ago
Qazi discusses a review of the BLUE-C trial and explains the rise of noninvasive CRC screening and surveillance options, but highlights the need for colonoscopy nonetheless.